# US 12,109,215 B2 · Combination therapies for inhibition of polo-like kinase 4

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,109,215 B2
- Document ID: US12109215B2
- Status: Granted
- Kind: B2
- Application number: 16/644,633
- Filed: 2018-09-07
- Published: 2021-03-04
- Granted: 2024-10-08
- Earliest claimed: 2017-09-08
- Assignees: University Health Network
- Applicants: University Health Network
- Inventors: Jacqueline M. Mason; Mark R. Bray; Tak Wah Mak; Graham Fletcher
- Web page: https://patentgrep.com/patent/US12109215B2

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- C07D 413/14: containing three or more hetero rings
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

## Claims

### Claim 1

A method for treating colon cancer, comprising:
administering to a subject an effective amount of a compound represented by the formula:
or a pharmaceutically acceptable salt thereof and an effective amount of a PD-1 inhibitor.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the PD-1 inhibitor is an antibody or an antigen binding fragment thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the PD-1 inhibitor is a monoclonal antibody or an antigen binding fragment thereof.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the PD-1 inhibitor restores anti-tumor T-cell activity.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the PD-1 inhibitor blocks T-cell-inhibitory cell activity.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the PD-1 inhibitor is one selected from pembrolizumab, and nivolumab.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the PD-1 inhibitor is one selected from JS001, SHR-1210, BGB-A317, IBI-308 and REGN2810.

### Claim 8

A method for treating colon cancer, comprising:
administering to a subject an effective amount of a compound represented by the formula:
or a pharmaceutically acceptable salt thereof and an effective amount of durvalumab.